KRRO Key Statistics, Chart & Performance
The current stock price of KRRO is 9.5 USD. In the past month the price increased by 21.33%. In the past year, price decreased by -73.06%.
KRRO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About KRRO
Company Profile
Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company is headquartered in Cambridge, Massachusetts and currently employs 87 full-time employees. The company went IPO on 2019-10-03. The firm discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The firm is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Company Info
KORRO BIO INC
One Kendall Square. Building 600-700, Suite 6-401
Cambridge MASSACHUSETTS US
Employees: 87
Phone: 16174681999
KORRO BIO INC / KRRO FAQ
Can you describe the business of KORRO BIO INC?
Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company is headquartered in Cambridge, Massachusetts and currently employs 87 full-time employees. The company went IPO on 2019-10-03. The firm discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The firm is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Can you provide the latest stock price for KORRO BIO INC?
The current stock price of KRRO is 9.5 USD. The price increased by 3.83% in the last trading session.
What is the dividend status of KORRO BIO INC?
KRRO does not pay a dividend.
What is the ChartMill rating of KORRO BIO INC stock?
KRRO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the market cap for KORRO BIO INC?
KORRO BIO INC (KRRO) has a market capitalization of 89.49M USD. This makes KRRO a Micro Cap stock.
Can you provide the upcoming earnings date for KORRO BIO INC?
KORRO BIO INC (KRRO) will report earnings on 2026-03-16, after the market close.
Who owns KORRO BIO INC?
You can find the ownership structure of KORRO BIO INC (KRRO) on the Ownership tab.
KRRO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to KRRO. When comparing the yearly performance of all stocks, KRRO is a bad performer in the overall market: 98.58% of all stocks are doing better.
KRRO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KRRO. No worries on liquidiy or solvency for KRRO as it has an excellent financial health rating, but there are worries on the profitability.
KRRO Financial Highlights
Over the last trailing twelve months KRRO reported a non-GAAP Earnings per Share(EPS) of -9.41. The EPS increased by 71.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.73% | ||
| ROE | -89.28% | ||
| Debt/Equity | 0 |
KRRO Forecast & Estimates
16 analysts have analysed KRRO and the average price target is 45.9 USD. This implies a price increase of 383.16% is expected in the next year compared to the current price of 9.5.